

Calogero Camma

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6809204/calogero-camma-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19
papers

649
citations

13
h-index

19
g-index

19
ext. papers

779
ext. citations

7.1
avg, IF

3.09
L-index

#	Paper	IF	Citations
19	Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis.. <i>Alimentary Pharmacology and Therapeutics</i> , 2022 ,	6.1	2
18	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Gut</i> , 2021 ,	19.2	21
17	Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals. <i>Liver International</i> , 2021 , 41, 2179-2188	7.9	1
16	Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization?. <i>Liver International</i> , 2021 , 41, 1105-1116	7.9	3
15	NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. <i>Liver International</i> , 2021 , 41, 2712-2719	7.9	3
14	Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study. <i>Liver International</i> , 2018 , 38, 715-723	7.9	15
13	Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?. <i>Liver International</i> , 2018 , 38, 2108-2116	7.9	13
12	A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. <i>Liver International</i> , 2017 , 37, 1157-1166	7.9	53
11	Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. <i>Liver International</i> , 2017 , 37, 1389-1396	7.9	26
10	Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 617-627	6.1	94
9	Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 688-695	6.1	104
8	Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis. <i>Digestive and Liver Disease</i> , 2015 , 47, 324-30	3.3	30
7	Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2014 , 59, 1692-705	11.2	64
6	Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014 , 46, 936-42	3.3	14
5	Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. <i>Journal of Hepatology</i> , 2013 , 59, 658-66	13.4	34
4	Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. <i>Hepatology</i> , 2013 , 57, 1046-54	11.2	78
3	Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2012 , 56, 850-60	11.2	91

2	Letter: liver dysfunction and survival in hepatocellular carcinoma treated by transarterial chemoembolisation [Authors' Reply]. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 862-863	6.1	1
1	Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma. <i>Liver Cancer International</i> ,	0.8	2